| P2093 | author name string | A Klabatsa | |
| | J P C Steele | |
| P2860 | cites work | The European mesothelioma epidemic | Q24650064 |
| | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops | Q28210619 |
| | The alpha folate receptor is highly activated in malignant pleural mesothelioma | Q31928563 |
| | Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma | Q33180838 |
| | Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study | Q33185691 |
| | Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Q33329809 |
| | Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP) | Q33338541 |
| | A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma | Q33341861 |
| | Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. | Q33401558 |
| | Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma | Q34107623 |
| | Pemetrexed disodium, a novel antifolate with multiple targets | Q34119634 |
| | Prospects for an SV40 vaccine | Q34178002 |
| | Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | Q34214330 |
| | A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group | Q34295028 |
| | Prognostic factors in mesothelioma | Q34522996 |
| | Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine | Q34523011 |
| | The role of gemcitabine in the treatment of malignant mesothelioma | Q34523019 |
| | New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents | Q34523037 |
| | Chemotherapy for malignant pleural mesothelioma: past results and recent developments | Q35074838 |
| | BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112 | Q35536471 |
| | Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development | Q35789268 |
| | Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma | Q35839893 |
| | High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study | Q35994031 |
| | High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma | Q36620561 |
| | Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma | Q36643866 |
| | Weekly high-dose cisplatin in malignant pleural mesothelioma | Q36738779 |
| | Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. | Q37432550 |
| | Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma | Q39447961 |
| | Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience | Q40232251 |
| | Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study | Q40618320 |
| | Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion | Q40723534 |
| | Diffuse malignant mesothelioma. Prospective evaluation of 69 patients | Q40844231 |
| | Analysis of current trends in United States mesothelioma incidence | Q40906672 |
| | Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience | Q41688263 |
| | The new front line treatment for malignant pleural mesothelioma? | Q43059612 |
| | Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma | Q43634484 |
| | A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study | Q43997685 |
| | Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. | Q44267257 |
| | Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma | Q44405249 |
| | A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma | Q44649986 |
| | Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). | Q44844685 |
| | Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma | Q45740888 |
| P433 | issue | 3 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 345-351 | |
| P577 | publication date | 2005-01-27 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Chemotherapy options and new advances in malignant pleural mesothelioma | |
| P478 | volume | 16 | |